Medworld医疗世界为您提供准确、及时、有用的医疗器械行业及医疗圈的市场动态,产品信息,技术进展等资讯!来源: Business of MDDIAlcon's anticipated split from Novartis has yet to be completed but the eye care business already is looking for ways to build out its portfolio for when it becomes a standalone company. Alcon reported Wednesday that it has acquired Tear Film Innovations, a private company that makes the iLux device used to treat Meibomian Gland Dysfunction, a leading cause of dry eye.The news comes at the end of what has been a bumpy year for Alcon, which was acquired by Novartis in 2011 for $12.9 billion.In June Novartis reported plans to split from Alcon, which will create a new Switzerland-based company. Just a couple months later, Alcon voluntarily pulled all versions of its Cypass Micro-Stent from the global market
………………………………